Pulmonary hypertension in sickle cell disease

Area of Science:

• Cardiology
• Hematology
• Pulmonology

Background:

• Pulmonary hypertension (PH) is a serious complication of sickle cell disease (SCD), affecting up to 30% of adult patients.
• PH in SCD significantly increases mortality risk (40-50% within 2 years), even with mild pressure elevations.
• The exact causes of PH in SCD are complex and likely multifactorial, involving hemolysis, nitric oxide issues, and other factors.

Purpose of the Study:

• To review the prevalence, pathogenesis, diagnosis, and current treatment strategies for pulmonary hypertension in sickle cell disease.
• To highlight the diagnostic challenges and the importance of early screening for PH in SCD patients.

Main Methods:

• Review of current literature on pulmonary hypertension in sickle cell disease.
• Discussion of diagnostic criteria, including Doppler echocardiography and tricuspid regurgitant jet velocity (TRV) screening.
• Analysis of potential therapeutic approaches, including sickle cell-specific treatments and PH-targeted therapies.

Main Results:

• Pulmonary hypertension is prevalent in SCD, with significant associated mortality.
• Clinical symptoms of PH often overlap with SCD anemia, complicating diagnosis.
• Doppler echocardiography with TRV measurement is the recommended screening tool, with PH defined as TRV ≥ 2.5 m/s.

Conclusions:

• Effective management of PH in SCD requires early detection through screening and a comprehensive approach.
• Treatment strategies involve optimizing SCD care, addressing contributing factors, and considering PH-specific medications.
• Further research into the pathobiology and clinical trials for PH in SCD are essential to improve patient outcomes.